U.S., Feb. 19 -- ClinicalTrials.gov registry received information related to the study (NCT03836690) titled 'Transfer of Effector Memory T Cells (Tem) Following Allogeneic Stem Cell Transplantation' on Jan. 10.
Brief Summary: RATIONALE: Following stem cell transplantation, a major risk is graft-versus-host disease (GVHD). This occurs when donor immune cells that have been infused recognise the host's cells as 'foreign' and attack these cells. Prevention of GVHD relies upon depletion of donor immune T cells or drugs that block T cell function. However, these methods also increase the risk of life threatening infection. There is an important unmet need for better means of accelerating immune recovery following stem cell transplantation while...